A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).
The purpose of this study is to assess if continuation therapy with atezolizumab in combination with next-line chemotherapy (carboplatin + gemcitabine) will improve PFS in patients with cisplatin-ineligible metastatic urothelial carcinoma as compared to historical controls.
- IRB Number: 1809401454 (GU17-295)
- Research Study Identifier: TX9408
- Principal Investigator: Nabil Adra, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required